

## **AMICUS SA RECEIVES SUPPORT AND GROWTH CAPITAL FROM HBM HEALTHCARE INVESTMENTS**

**PRESS RELEASE 15: Amicus SA announced today a strategic expansion of its shareholder base. HBM Healthcare Investments, a well-respected Swiss investor in innovative healthcare companies, took a significant minority equity stake in Amicus.**

**Baar, Switzerland, April 27, 2017:** Amicus SA, a Switzerland-based company with pharmaceutical businesses across the CEE region, announced the expansion of its shareholder base today. HBM Healthcare Investments (Cayman) Ltd., a wholly-owned subsidiary of HBM Healthcare Investments, Ltd. of Zug, Switzerland, has become a significant minority shareholder in Amicus committing an equity investment of EUR 20m. HBM is a leading investor in pharmaceutical and biotechnology companies worldwide. The company's founders and senior executives still retain the majority stake after the financing.

"We are delighted to welcome HBM Healthcare Investments, a widely-respected pharma and biotech investor, as a keystone shareholder in Amicus", commented Petr Nemeč, Founding Partner of Amicus S.A.. "They bring to our company enhanced corporate governance, a wealth of new contacts, ideas and great energy. Further, with this significant cash injection, HBM is putting Amicus in pole position to accelerate its growth in Central and Eastern Europe and beyond. On a personal basis, I'd like to add that I am thrilled to re-establish the productive and friendly relationship that our management group enjoyed with HBM previously," continued Nemeč. "Re-uniting with HBM marks a full turning of the circle, and I am simply delighted to work with the HBM team once again. They are a positive business force."

"The HBM investment is yet another confirmation that Amicus S.A. is fast becoming the unavoidable alternative partner for those healthcare companies that choose not to undertake their own marketing and distribution in Central & Eastern European countries," remarked Jean-Michel Lespinasse, CEO of Amicus SA "Through the biotech and pharmaceutical network of HBM, as well as via leveraging our newly-expanded financial resources, we will accelerate the growth of our portfolio, and further expand our geographical reach."

### **About Amicus S.A.**

Amicus subsidiaries operate in the West Balkan and Baltic countries, and the company is expanding to Bulgaria and Hungary in the course of 2017. Amicus has gathered outstanding pharmaceutical, medical device and OTC industry talent across these countries; the company specializes in representing research-based pharmaceutical, medical equipment and branded self-care brands in countries where the originators decide not to maintain a direct presence.

Founded in 2014, Amicus is privileged to represent leading healthcare companies like Alcon, Bristol Myers Squibb, Cardinal Health, Expanscience, Grupo Ferrer, General Electric, Genexo, Pfizer, PharmaNutra and Salvat Biotech, amongst others.

For more information about Amicus, please visit: [www.amicuspharma.eu](http://www.amicuspharma.eu)

## **About HBM Healthcare**

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

For further information about HBM, please visit: [www.hbmhealthcare.com/en/](http://www.hbmhealthcare.com/en/)

### **Contact:**

**Maja Boskovic, Public Affairs Officer, Amicus**

Maja.Boskovic@amicuspharma.eu, Tel: +381 11 4426 321